Panacos Pharmaceuticals, Inc. (Nasdaq:PANC), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, today announced the completion of preclinical studies indicating that their lead drug candidate, bevirimat (PA-457), is non-teratogenic, meaning it did not cause fetal malformations in the models used in the studies. The findings from these studies were published today as an abstract in the Conference Abstract Book of the XVI International AIDS Conference.
